FMTX · Forma Therapeutics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $0 | $100.56M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $125.66M | $93.37M |
| SG&A | $48.33M | $30.78M |
| Total Operating Expenses | $173.99M | $124.21M |
| D&A | $1.57M | $1.28M |
| Operating Income | ($173.99M) | ($124.21M) |
| Interest Expense | - | - |
| Income Tax | $154.0K | ($29.72M) |
| Net Income | ($172.96M) | ($70.41M) |
| EPS - Basic | - | ($3.22) |
| EPS - Diluted | - | ($3.22) |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $77.42M | $282.69M |
| Accounts Receivable | - | $0 |
| Inventory | - | - |
| Accounts Payable | $4.14M | $4.29M |
| Current Assets | $486.40M | $654.45M |
| Total Assets | $561.06M | $680.97M |
| Current Liabilities | $35.09M | $31.70M |
| Long-term Debt | - | - |
| Total Liabilities | $62.70M | $32.73M |
| Stockholders' Equity | $498.36M | $648.24M |
| Retained Earnings | ($230.37M) | ($57.41M) |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($149.79M) | ($95.42M) |
| Investing Cash Flow | ($55.38M) | ($345.82M) |
| Financing Cash Flow | ($459.0K) | $552.60M |
| CapEx | $4.18M | $249.0K |
| Free Cash Flow | ($153.97M) | ($95.67M) |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | -123.5% |
| EBITDA margin | - | -122.3% |
| Net margin | - | -70.0% |
| Free cash flow margin | - | -95.1% |
| FCF / Net income | 0.89 | 1.36 |
| R&D / Revenue | - | 92.8% |
| SG&A / Revenue | - | 30.6% |
| Effective tax rate | - | - |
| Return on assets | -30.8% | -10.3% |
| Return on equity | -34.7% | -10.9% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 13.86 | 20.65 |
| Quick ratio | 13.86 | 20.65 |
| Cash ratio | 2.21 | 8.92 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.13 | 1.05 |
| Liabilities / Assets | 0.11 | 0.05 |
| Efficiency | ||
| Asset turnover | 0.00 | 0.15 |
| Inventory turnover | - | - |
| Days sales outstanding | - | 0d |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | -100.0% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -40.1% | - |
| Net income growth (YoY) | -145.6% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -60.9% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -23.1% | - |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
2.60
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Forma Therapeutics Holdings against the 5 most active filers in the same SIC group.